A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Healthy Participants
Primary Purpose
Healthy Participants
Status
Recruiting
Phase
Phase 1
Locations
Germany
Study Type
Interventional
Intervention
BMS-986326
Placebo matching BMS-986326
Multiple Ascending Dose SC
Multiple Ascending Dose Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Healthy Participants focused on measuring BMS-986326, Healthy participants
Eligibility Criteria
Inclusion Criteria:
- In good health, as determined by the investigator based on a physical examination at screening
- Body mass index (BMI) ≥ 18 and ≤ 30 kg/m^2 at screening
- Afebrile, with supine systolic blood pressure (BP) ≥ 90 and ≤ 140 mmHg and supine diastolic BP ≥ 50 and ≤ 90 mmHg and heart rate ≥ 50 and ≤ 90 bpm at screening
- Male participants and women not of child-bearing potential (WNOCBP) are eligible to participate in all cohorts (A1-B3). Women of child-bearing potential (WOCBP) are only eligible for the subcutaneous (SC) cohorts (B1-B3)
- Must agree to follow specific methods of contraception, if applicable
Exclusion Criteria:
- Women who are pregnant or lactating
- History of, or active, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
- Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, echocardiogram (ECG), or clinical laboratory determinations beyond what is consistent with healthy participants
- History of serious adverse reaction or hypersensitivity to any (subcutaneous) SC- or (intravenous) IV-administered biological therapeutic, including IV immunoglobulins and human blood products
Other protocol-defined inclusion/exclusion criteria apply
Sites / Locations
- Local Institution - 0001Recruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm Type
Experimental
Experimental
Placebo Comparator
Placebo Comparator
Placebo Comparator
Experimental
Arm Label
Active Treatment (BMS 986326) IV
Active Treatment (BMS 986326) SC
Placebo IV
Placebo SC
Multiple Ascending Dose Placebo SC
Multiple Ascending Dose SC
Arm Description
Intravenous (IV)
Subcutaneous (SC)
Placebo
BMS 986326 SC
Outcomes
Primary Outcome Measures
Number of participants with adverse events (AEs)
Number of participants with clinical laboratory abnormalities
Number of participants with vital sign abnormalities
Number of participants with electrocardiogram (ECG) abnormalities
Number of participants with physical examinations abnormalities
Secondary Outcome Measures
Maximum observed serum concentration (Cmax)
Time of maximum observed serum concentration (Tmax)
Area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-T)]
Geometric mean ratios of test (SC) vs reference (IV): Area under the serum concentration-time curve extrapolated to infinite time [AUC(INF)]
Change in regulatory T cells (Treg) count
Change in Treg-to-conventional CD4 cells [Treg-to-Tconv] ratio
Number of participants with anti-drug antibodies
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04736134
Brief Title
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Healthy Participants
Official Title
A Double-blind, Placebo-controlled, Randomized, Single and Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous Administration of BMS-986326 in Healthy Participants
Study Type
Interventional
2. Study Status
Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 3, 2021 (Actual)
Primary Completion Date
March 19, 2024 (Anticipated)
Study Completion Date
March 19, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bristol-Myers Squibb
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate the safety, tolerability, drug levels, drug effects, and immunogenicity of BMS-986326 after infusion or injection in healthy participants. The results of this study will guide the selection of the dose range, dosing frequency, and the route of administration for future studies of BMS-986326 in participants with immune-mediated diseases.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy Participants
Keywords
BMS-986326, Healthy participants
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
88 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Active Treatment (BMS 986326) IV
Arm Type
Experimental
Arm Description
Intravenous (IV)
Arm Title
Active Treatment (BMS 986326) SC
Arm Type
Experimental
Arm Description
Subcutaneous (SC)
Arm Title
Placebo IV
Arm Type
Placebo Comparator
Arm Title
Placebo SC
Arm Type
Placebo Comparator
Arm Title
Multiple Ascending Dose Placebo SC
Arm Type
Placebo Comparator
Arm Description
Placebo
Arm Title
Multiple Ascending Dose SC
Arm Type
Experimental
Arm Description
BMS 986326 SC
Intervention Type
Biological
Intervention Name(s)
BMS-986326
Intervention Description
Specified dose on specified days
Intervention Type
Other
Intervention Name(s)
Placebo matching BMS-986326
Intervention Description
Specified dose on specified days
Intervention Type
Biological
Intervention Name(s)
Multiple Ascending Dose SC
Intervention Description
Specified dose on specified days
Intervention Type
Other
Intervention Name(s)
Multiple Ascending Dose Placebo
Intervention Description
Specified dose on specified days
Primary Outcome Measure Information:
Title
Number of participants with adverse events (AEs)
Time Frame
Up to 175 days
Title
Number of participants with clinical laboratory abnormalities
Time Frame
Up to 175 days
Title
Number of participants with vital sign abnormalities
Time Frame
Up to 175 days
Title
Number of participants with electrocardiogram (ECG) abnormalities
Time Frame
Up to 175 days
Title
Number of participants with physical examinations abnormalities
Time Frame
Up to 175 days
Secondary Outcome Measure Information:
Title
Maximum observed serum concentration (Cmax)
Time Frame
Up to 175 days
Title
Time of maximum observed serum concentration (Tmax)
Time Frame
Up to 175 days
Title
Area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-T)]
Time Frame
Up to 175 days
Title
Geometric mean ratios of test (SC) vs reference (IV): Area under the serum concentration-time curve extrapolated to infinite time [AUC(INF)]
Time Frame
Up to 175 days
Title
Change in regulatory T cells (Treg) count
Time Frame
Up to 175 days
Title
Change in Treg-to-conventional CD4 cells [Treg-to-Tconv] ratio
Time Frame
Up to 175 days
Title
Number of participants with anti-drug antibodies
Time Frame
Up to 175 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
In good health, as determined by the investigator based on a physical examination at screening
Body mass index (BMI) ≥ 18 and ≤ 30 kg/m^2 at screening
Afebrile, with supine systolic blood pressure (BP) ≥ 90 and ≤ 140 mmHg and supine diastolic BP ≥ 50 and ≤ 90 mmHg and heart rate ≥ 50 and ≤ 90 bpm at screening
Male participants are eligible to participate in cohorts (A1-B3).Women not of child bearing potential (WNOCBP) are eligible to participate in all cohorts (A1-B3 and C1-C2) Women of child-bearing potential (WOCBP) are only eligible for the subcutaneous (SC) cohorts (B1-B3 and C1-C2)
Must agree to follow specific methods of contraception, if applicable
Exclusion Criteria:
Women who are pregnant or lactating
History of, or active, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, echocardiogram (ECG), or clinical laboratory determinations beyond what is consistent with healthy participants
History of serious adverse reaction or hypersensitivity to any (subcutaneous) SC- or (intravenous) IV-administered biological therapeutic, including IV immunoglobulins and human blood products
Other protocol-defined inclusion/exclusion criteria apply
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
BMS Study Connect Contact Center www.BMSStudyConnect.com
Phone
855-907-3286
Email
Clinical.Trials@bms.com
First Name & Middle Initial & Last Name or Official Title & Degree
First line of the email MUST contain NCT # and Site #.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bristol-Myers Squibb
Organizational Affiliation
Bristol-Myers Squibb
Official's Role
Study Director
Facility Information:
Facility Name
Local Institution - 0001
City
Berlin
ZIP/Postal Code
10117
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0001
12. IPD Sharing Statement
Links:
URL
https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Description
BMS Clinical Trial Information
URL
https://www.bmsstudyconnect.com/s/US/English/USenHome
Description
BMS Clinical Trial Patient Recruiting
URL
https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm
Description
FDA Safety Alerts and Recalls
Learn more about this trial
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Healthy Participants
We'll reach out to this number within 24 hrs